The transition from controlled clinical trials to real-world clinical practice often reveals critical gaps between research efficacy and practical outcomes, particularly for complex autoimmune conditions requiring precision therapy. This tension becomes especially pronounced with newer biologics targeting inflammatory pathways where patient heterogeneity significantly impacts treatment response.
The REVEAL study's interim analysis examined 50 patients across 25 Italian rheumatology centers who initiated anifrolumab, a type I interferon receptor antagonist, for active systemic lupus erythematosus. This represents the first substantial real-world dataset for anifrolumab outside controlled trial environments. The observational design captures routine clinical decision-making patterns and patient characteristics that typically differ from randomized controlled trial populations, including those with more complex comorbidity profiles and varied disease presentations.
This real-world evidence fills a crucial knowledge gap, as anifrolumab's approval was based primarily on controlled trials with strict inclusion criteria that may not reflect the diverse patient populations seen in clinical practice. The interferon pathway's role in lupus pathogenesis varies considerably among patients, making real-world response patterns particularly valuable for treatment optimization. The study's prospective design and multi-center approach across tertiary centers provides more generalizable insights than single-center case series. However, the interim nature limits long-term safety and efficacy assessments, and the Italian healthcare context may not translate directly to other healthcare systems. The 6-month timeframe also restricts evaluation of sustained responses and delayed adverse events that could influence treatment durability decisions.